CAMK2B

Summary

CAMK2B (calcium/calmodulin dependent protein kinase II beta, HGNC:1461) is a protein-coding gene on chromosome 7p13, encoding Calcium/calmodulin-dependent protein kinase type II subunit beta (Q13554). Calcium/calmodulin-dependent protein kinase that functions autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, and is involved in dendritic spine and synapse formation, neuronal plasticity and regulation of sarcoplasmic reticulum Ca(2+) transport in skeletal mu….

The product of this gene belongs to the serine/threonine protein kinase family and to the Ca(2+)/calmodulin-dependent protein kinase subfamily. Calcium signaling is crucial for several aspects of plasticity at glutamatergic synapses. In mammalian cells, the enzyme is composed of four different chains: alpha, beta, gamma, and delta. The product of this gene is a beta chain. It is possible that distinct isoforms of this chain have different cellular localizations and interact differently with calmodulin. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 816 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability, autosomal dominant 40 (Definitive, GenCC) — +2 more curated relationships
• GWAS associations: 6
• Clinical variants (ClinVar): 944 total — 8 pathogenic, 8 likely-pathogenic
• Phenotypes (HPO): 64
• Druggable target: yes — 25 molecules with ChEMBL bioactivity
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001220

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1461
Approved symbol	CAMK2B
Name	calcium/calmodulin dependent protein kinase II beta
Location	7p13
Locus type	gene with protein product
Status	Approved
Aliases	CAM2, CAMK2, CaMKIIβ
Ensembl gene	ENSG00000058404
Ensembl biotype	protein_coding
OMIM	607707
Entrez	816

Gene structure

Transcript identifiers

Ensembl transcripts: 127 — 105 protein_coding, 10 protein_coding_CDS_not_defined, 9 nonsense_mediated_decay, 3 retained_intron

ENST00000258682, ENST00000346990, ENST00000347193, ENST00000350811, ENST00000353185, ENST00000353625, ENST00000358707, ENST00000395747, ENST00000395749, ENST00000415369, ENST00000421607, ENST00000424197, ENST00000425809, ENST00000427209, ENST00000433930, ENST00000440254, ENST00000462128, ENST00000466584, ENST00000470984, ENST00000484972, ENST00000489429, ENST00000495819, ENST00000497127, ENST00000497584, ENST00000523845, ENST00000700233, ENST00000700234, ENST00000700235, ENST00000700236, ENST00000700237, ENST00000700238, ENST00000700239, ENST00000700240, ENST00000700241, ENST00000700242, ENST00000700243, ENST00000700244, ENST00000700245, ENST00000700246, ENST00000700283, ENST00000700284, ENST00000700285, ENST00000700286, ENST00000700287, ENST00000700288, ENST00000700289, ENST00000700290, ENST00000700291, ENST00000700292, ENST00000896817, ENST00000896818, ENST00000896819, ENST00000896820, ENST00000896821, ENST00000896822, ENST00000896823, ENST00000896824, ENST00000896825, ENST00000896826, ENST00000896827, ENST00000896828, ENST00000896829, ENST00000896830, ENST00000896831, ENST00000896832, ENST00000896833, ENST00000896834, ENST00000896835, ENST00000896836, ENST00000896837, ENST00000896838, ENST00000896839, ENST00000896840, ENST00000896841, ENST00000896842, ENST00000896843, ENST00000896844, ENST00000896845, ENST00000896846, ENST00000896847, ENST00000943311, ENST00000943312, ENST00000943313, ENST00000943314, ENST00000943315, ENST00000943316, ENST00000943317, ENST00000943318, ENST00000943319, ENST00000943320, ENST00000943321, ENST00000943322, ENST00000943323, ENST00000943324, ENST00000943325, ENST00000943326, ENST00000943327, ENST00000943328, ENST00000943329, ENST00000943330, ENST00000943331, ENST00000943332, ENST00000943333, ENST00000943334, ENST00000943335, ENST00000943336, ENST00000943337, ENST00000943338, ENST00000943339, ENST00000943340, ENST00000943341, ENST00000943342, ENST00000943343, ENST00000943344, ENST00000943345, ENST00000943346, ENST00000943347, ENST00000943348, ENST00000943349, ENST00000943350, ENST00000943351, ENST00000943352, ENST00000943353, ENST00000943354, ENST00000943355, ENST00000943356, ENST00000943357

RefSeq mRNA: 9 — MANE Select: NM_001220 NM_001220, NM_001293170, NM_172078, NM_172079, NM_172080, NM_172081, NM_172082, NM_172083, NM_172084

CCDS: CCDS43573, CCDS5483, CCDS5484, CCDS5485, CCDS5486, CCDS5487, CCDS5488, CCDS5489

Canonical transcript exons

ENST00000395749 — 24 exons

Exon	Start	End
ENSE00000522115	44229388	44229501
ENSE00001522695	44217154	44219522
ENSE00001522700	44325357	44325594
ENSE00001617876	44228796	44228924
ENSE00003459249	44243425	44243527
ENSE00003467097	44220826	44220901
ENSE00003493389	44254542	44254607
ENSE00003497281	44220060	44220294
ENSE00003503497	44234390	44234461
ENSE00003517138	44263005	44263064
ENSE00003519113	44232822	44232866
ENSE00003523373	44247120	44247192
ENSE00003530079	44239589	44239663
ENSE00003588775	44243250	44243333
ENSE00003611913	44242560	44242654
ENSE00003616190	44231006	44231054
ENSE00003618995	44220616	44220710
ENSE00003638925	44241700	44241783
ENSE00003639508	44258872	44258926
ENSE00003653672	44234639	44234676
ENSE00003673431	44240707	44240749
ENSE00003689662	44226516	44226644
ENSE00003979433	44242218	44242340
ENSE00003979459	44284131	44284225

Expression profiles

Bgee: expression breadth ubiquitous, 233 present calls, max score 99.36.

FANTOM5 (CAGE): breadth broad, TPM avg 10.0089 / max 602.8518, expressed in 539 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
83867	7.6325	486
83868	1.2388	206
83857	0.3732	84
83858	0.2906	88
83861	0.2822	27
83863	0.0872	45
83862	0.0483	10
83869	0.0313	12
83865	0.0246	6

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar cortex	UBERON:0002129	99.36	gold quality
cerebellar hemisphere	UBERON:0002245	99.36	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.30	gold quality
cerebellum	UBERON:0002037	99.25	gold quality
cerebellar vermis	UBERON:0004720	99.07	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.65	gold quality
paraflocculus	UBERON:0005351	98.39	gold quality
nucleus accumbens	UBERON:0001882	98.36	gold quality
parietal lobe	UBERON:0001872	98.21	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.16	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	98.15	gold quality
right frontal lobe	UBERON:0002810	98.13	gold quality
putamen	UBERON:0001874	98.12	gold quality
postcentral gyrus	UBERON:0002581	98.11	gold quality
caudate nucleus	UBERON:0001873	98.10	gold quality
CA1 field of hippocampus	UBERON:0003881	98.07	gold quality
Brodmann (1909) area 10	UBERON:0013541	97.99	gold quality
prefrontal cortex	UBERON:0000451	97.86	gold quality
frontal cortex	UBERON:0001870	97.79	gold quality
frontal lobe	UBERON:0016525	97.79	gold quality
superior frontal gyrus	UBERON:0002661	97.78	gold quality
Ammon’s horn	UBERON:0001954	97.67	gold quality
cingulate cortex	UBERON:0003027	97.58	gold quality
anterior cingulate cortex	UBERON:0009835	97.55	gold quality
pons	UBERON:0000988	97.52	gold quality
Brodmann (1909) area 46	UBERON:0006483	97.30	gold quality
frontal pole	UBERON:0002795	97.28	gold quality
neocortex	UBERON:0001950	97.21	gold quality
apex of heart	UBERON:0002098	97.21	gold quality
telencephalon	UBERON:0001893	97.18	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-GEOD-137537	yes	1510.19
E-MTAB-7316	yes	1393.86
E-HCAD-35	yes	39.75
E-GEOD-84465	yes	7.40
E-GEOD-83139	yes	3.74
E-MTAB-6058	no	221.14
E-ANND-3	no	3.53
E-HCAD-5	no	2.30

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

62 targeting CAMK2B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-6715B-5P	99.64	69.63	1420
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-3136-3P	99.57	66.59	781

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 25)

• mRNA levels are elevated in the frontal cortex in schizophrenia. (PMID:11042361)
• Four distinct isoforms of CAMKII were isolated. Two of them were characterized as CaMKII alpha and beta subunits.expression is developmentally regulated in both human fetal and adult brain to different degrees (PMID:11710563)
• role in cell communication (PMID:11889801)
• CaMK II regulates c-FLIP expression and phosphorylation, thus modulating Fas-mediated signaling in glioma cells (PMID:12496285)
• exercise increases the activity of CaMKII in skeletal muscle, suggesting that it may have a role in regulating skeletal muscle function and metabolism during exercise in humans (PMID:14565989)
• measured differences in CaMKII binding affinities for CaM play a minor role in the autophosphorylation of the enzyme, largely dictated by autophosphorylation rate for alpha, beta, gamma and delta isoforms (PMID:14722083)
• the function of CaMK II is essential for PAF-induced macrophage priming, while CaMK IV is not specific for priming by PAF and appears to have a direct link in TLR4-mediated events (PMID:15665723)
• presence of a CaMKIIbeta isoform that can target the SR presumably via its membrane anchor alphaKAP defines a previously unrecognized Ca2+/CaM regulatory system in myocardium (PMID:15792370)
• thrombomodulin induces Ca2+ signals and nitric oxide synthesis through EGFR and calmodulin kinase II (PMID:16126727)
• The expression of CaMKII beta was significantly elevated in schizophrenia and in depression. (PMID:16247765)
• expression significantly elevated in frontal cortex in schizophrenia & depression; because CaMKIIbeta influences expression of neuroreceptors & neural outgrowth & pruning, altered expression in schizophrenia or depression may contribute to these diseases (PMID:16247765)
• regulated degradation of liprinalpha1 is important for proper LAR receptor distribution, and could provide a mechanism for localized control of dendrite and synapse morphogenesis by activity and CaMKII. (PMID:17419996)
• These FLIM versions of Camui could be useful for elucidating the function of CaMKII both in vitro and in vivo. (PMID:18302935)
• The novel cGMP/PKG/ROS/calmodulin/CaMKII signaling pathway may regulate cardiomyocyte excitability by opening K(ATP) channels and contribute to cardiac protection against ischemia-reperfusion injury. (PMID:21479273)
• Characterization of a central Ca2+/calmodulin-dependent protein kinase IIalpha/beta binding domain in densin that selectively modulates glutamate receptor subunit phosphorylation. (PMID:21610080)
• Promoter methylations of CAMK2B and ARFGEF1 are novel epigenetic markers identified in breast cancer cell lines. (PMID:21871176)
• Study presents the crystal structure of an autoinhibited full-length human CaMKII holoenzyme, revealing an unexpected compact arrangement of kinase domains docked against a central hub, with the calmodulin-binding sites completely inaccessible. (PMID:21884935)
• beta-carotene reverses the IL-1beta-mediated reduction in paraoxonase-1 expression via induction of the CaMKKII pathway in human endothelial cells (PMID:22750393)
• Due to similarity of structure variations, we suggest that these compounds may have an effect on beta-CaMKII and that sengesterone may have a similar efficacy as the control. (PMID:25045698)
• TGFbeta elevated the expression of CamK IIbeta and CamK IIdelta, while siRNA silencing of those two subtypes significantly reduced TGFbeta-mediated expression of collagen A1 and fibronectin 1. (PMID:28130256)
• The importance of CAMK2A and CAMK2B and their auto-phosphorylation in human brain function. (PMID:29100089)
• CaMKII regulates KCNQ1 at S484 during sustained beta-AR stimulation to inhibit IKs. The ability of CaMKII to inhibit IKs may contribute to arrhythmogenicity during HF. (PMID:29410121)
• Flexible linkers in CaMKII control the balance between activating and inhibitory autophosphorylation. (PMID:32149607)
• CaMKIIbeta in Neuronal Development and Plasticity: An Emerging Candidate in Brain Diseases. (PMID:33019657)
• Understanding the pathogenetic mechanisms underlying altered neuronal function associated with CAMK2B mutations. (PMID:37391113)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	camk2b1	ENSDARG00000011065
danio_rerio	camk2b2	ENSDARG00000100089
mus_musculus	Camk2b	ENSMUSG00000057897
rattus_norvegicus	Camk2b	ENSRNOG00000052080

Paralogs (22): CAMKK1 (ENSG00000004660), CAMK1G (ENSG00000008118), CAMK2A (ENSG00000070808), MYLK2 (ENSG00000101306), CAMKK2 (ENSG00000110931), STK11 (ENSG00000118046), STK33 (ENSG00000130413), PNCK (ENSG00000130822), DCLK1 (ENSG00000133083), CAMK1 (ENSG00000134072), MYLK3 (ENSG00000140795), CAMK2D (ENSG00000145349), MYLK4 (ENSG00000145949), PSKH2 (ENSG00000147613), CAMK2G (ENSG00000148660), PHKG2 (ENSG00000156873), PSKH1 (ENSG00000159792), DCLK3 (ENSG00000163673), CAMKV (ENSG00000164076), PHKG1 (ENSG00000164776), DCLK2 (ENSG00000170390), CAMK1D (ENSG00000183049)

Protein

Protein identifiers

Calcium/calmodulin-dependent protein kinase type II subunit beta — Q13554 (reviewed: Q13554)

All UniProt accessions (26): Q13554, A0A8V8TPG1, A0A8V8TPG6, A0A8V8TPH1, A0A8V8TPJ7, A0A8V8TPW6, A0A8V8TPX2, A0A8V8TPX9, A0A8V8TQ05, A0A8V8TQ06, A0A8V8TQ12, A0A8V8TQ13, A0A8V8TQ39, A0A8V8TQR5, A0A8V8TQS2, A0A8V8TQU0, A0A8V8TQU4, A0A8V8TR22, A0A8V8TR26, A0A8V8TR45, A4D2J9, E7EQE4, E7ERS6, E9PBE8, H7BXS4, H7BZC6

UniProt curated annotations — full annotation on UniProt →

Function. Calcium/calmodulin-dependent protein kinase that functions autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, and is involved in dendritic spine and synapse formation, neuronal plasticity and regulation of sarcoplasmic reticulum Ca(2+) transport in skeletal muscle. In neurons, plays an essential structural role in the reorganization of the actin cytoskeleton during plasticity by binding and bundling actin filaments in a kinase-independent manner. This structural function is required for correct targeting of CaMK2A, which acts downstream of NMDAR to promote dendritic spine and synapse formation and maintain synaptic plasticity which enables long-term potentiation (LTP) and hippocampus-dependent learning. In developing hippocampal neurons, promotes arborization of the dendritic tree and in mature neurons, promotes dendritic remodeling. Also regulates the migration of developing neurons. Participates in the modulation of skeletal muscle function in response to exercise. In slow-twitch muscles, is involved in regulation of sarcoplasmic reticulum (SR) Ca(2+) transport and in fast-twitch muscle participates in the control of Ca(2+) release from the SR through phosphorylation of triadin, a ryanodine receptor-coupling factor, and phospholamban (PLN/PLB), an endogenous inhibitor of SERCA2A/ATP2A2. In response to interferon-gamma (IFN-gamma) stimulation, catalyzes phosphorylation of STAT1, stimulating the JAK-STAT signaling pathway. Phosphorylates reticulophagy regulator RETREG1 at ‘Ser-151’ under endoplasmic reticulum stress conditions which enhances RETREG1 oligomerization and its membrane scission and reticulophagy activity.

Subunit / interactions. CAMK2 is composed of 4 different chains: alpha (CAMK2A), beta (CAMK2B), gamma (CAMK2G), and delta (CAMK2D). The different isoforms assemble into homo- or heteromultimeric holoenzymes composed of 12 subunits with two hexameric rings stacked one on top of the other (PubMed:14722083, Ref.20). Interacts with SYNGAP1 and CAMK2N2. Interacts with MPDZ. Interacts with FOXO3. Interacts (when in a kinase inactive state not associated with calmodulin) with ARC; leading to target ARC to inactive synapses. Interacts with CAMK2N1; this interaction requires CAMK2B activation by Ca(2+).

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Sarcoplasmic reticulum membrane. Synapse.

Tissue specificity. Widely expressed. Expressed in adult and fetal brain. Expression is slightly lower in fetal brain. Expressed in skeletal muscle.

Post-translational modifications. Autophosphorylation of Thr-287 following activation by Ca(2+)/calmodulin. Phosphorylation of Thr-287 locks the kinase into an activated state.

Disease relevance. Intellectual developmental disorder, autosomal dominant 54 (MRD54) [MIM:617799] A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Activated by Ca(2+)/calmodulin. Binding of calmodulin results in conformational change that relieves intrasteric autoinhibition and allows autophosphorylation of Thr-287 which turns the kinase in a constitutively active form and confers to the kinase a Ca(2+)-independent activity.

Domain organisation. The CAMK2 protein kinases contain a unique C-terminal subunit association domain responsible for oligomerization.

Induction. Activity is induced in skeletal muscle during exercise.

Similarity. Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CaMK subfamily.

Isoforms (8)

UniProt ID	Names	Canonical?
Q13554-1	4	yes
Q13554-2	1, Beta
Q13554-3	2, Beta1, Beta’E
Q13554-4	3, Beta2
Q13554-5	5, Beta4, BetaE
Q13554-6	6, Beta6
Q13554-7	7, Beta7
Q13554-8	8

RefSeq proteins (9): NP_001211, NP_001280099, NP_742075, NP_742076, NP_742077, NP_742078, NP_742079, NP_742080, NP_742081 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR013543	Ca/CaM-dep_prot_kinase-assoc	Domain
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR032710	NTF2-like_dom_sf	Homologous_superfamily

Pfam: PF00069, PF08332

Enzyme classification (BRENDA):

• EC 2.7.11.17 — Ca2+/calmodulin-dependent protein kinase (BRENDA: 38 organisms, 300 substrates, 137 inhibitors, 35 Km, 17 kcat entries)

Substrate kinetics (BRENDA)

12 substrates with measured Km, best-characterized 12. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0071–178.29	13
BIOTINYLATED THR-ARG-SER-ALA-ILE-ARG-ARG-ALA-SER	0.0064–0.0158	4
GST-TAGGED GLUN2A	6.05–11.75	2
GST-TAGGED GLUN2B	0.35–5.93	2
MAP2	0.0007–0.0008	2
CALDESMON	0.0049	1
HISTONE IIIS	0.0445	1
LYS-LYS-ALA-LEU-ARG-ARG-GLN-GLU-ALA-VAL-ASP-ALA-	0.063	1
MICROTUBULE ASSOCIATED PROTEIN 2	0.0016	1
SYNTIDE-2	0.02	1
SYNTIDE-2 PEPTIDE	0.0221	1
MYELIN BASIC PROTEIN	—	0

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (78 total): helix 18, strand 15, modified residue 9, splice variant 9, sequence variant 9, compositionally biased region 4, region of interest 3, sequence conflict 3, turn 3, binding site 2, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
3BHH	X-RAY DIFFRACTION	2.4
7URY	X-RAY DIFFRACTION	2.64
7URW	X-RAY DIFFRACTION	3.11
7URZ	X-RAY DIFFRACTION	3.45

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13554-F1	72.35	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 136 (proton acceptor)

Ligand- & substrate-binding residues (2): 20–28; 43

Post-translational modifications (9): 17, 287, 306, 307, 367, 394, 397, 400, 401

Function

Pathways and Gene Ontology

Reactome pathways

61 pathways

ID	Pathway
R-HSA-111932	CaMK IV-mediated phosphorylation of CREB
R-HSA-3371571	HSF1-dependent transactivation
R-HSA-399719	Trafficking of AMPA receptors
R-HSA-438066	Unblocking of NMDA receptors, glutamate binding and activation
R-HSA-442729	CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
R-HSA-442982	Ras activation upon Ca2+ influx through NMDA receptor
R-HSA-5576892	Phase 0 - rapid depolarisation
R-HSA-5578775	Ion homeostasis
R-HSA-5673000	RAF activation
R-HSA-5673001	RAF/MAP kinase cascade
R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants
R-HSA-6802952	Signaling by BRAF and RAF1 fusions
R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF
R-HSA-877300	Interferon gamma signaling
R-HSA-9022692	Regulation of MECP2 expression and activity
R-HSA-936837	Ion transport by P-type ATPases
R-HSA-9609736	Assembly and cell surface presentation of NMDA receptors
R-HSA-9617324	Negative regulation of NMDA receptor-mediated neuronal transmission
R-HSA-9620244	Long-term potentiation
R-HSA-9649948	Signaling downstream of RAS mutants
R-HSA-9656223	Signaling by RAF1 mutants
R-HSA-9918481	Dengue Virus-Host Interactions
R-HSA-111885	Opioid Signalling
R-HSA-111933	Calmodulin induced events
R-HSA-111996	Ca-dependent events
R-HSA-111997	CaM pathway
R-HSA-112040	G-protein mediated events
R-HSA-112043	PLC beta mediated events
R-HSA-112314	Neurotransmitter receptors and postsynaptic signal transmission
R-HSA-112315	Transmission across Chemical Synapses

MSigDB gene sets: 485 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, MORF_RAGE, GOBP_DENDRITE_DEVELOPMENT, BENPORATH_ES_WITH_H3K27ME3, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, REACTOME_CREB1_PHOSPHORYLATION_THROUGH_THE_ACTIVATION_OF_CAMKII_CAMKK_CAMKIV_CASCASDE, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, RORA1_01, GOBP_REGULATION_OF_NEURONAL_SYNAPTIC_PLASTICITY, GOBP_SKELETAL_MUSCLE_ADAPTATION, GOBP_REGULATION_OF_DENDRITE_MORPHOGENESIS, GOBP_DENDRITIC_SPINE_DEVELOPMENT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_NEUROGENESIS

GO Biological Process (17): protein phosphorylation (GO:0006468), signal transduction (GO:0007165), nervous system development (GO:0007399), positive regulation of neuron projection development (GO:0010976), regulation of skeletal muscle adaptation (GO:0014733), cell differentiation (GO:0030154), protein autophosphorylation (GO:0046777), regulation of neuronal synaptic plasticity (GO:0048168), regulation of long-term neuronal synaptic plasticity (GO:0048169), regulation of synapse structural plasticity (GO:0051823), regulation of calcium ion transport (GO:0051924), long-term synaptic potentiation (GO:0060291), regulation of dendritic spine development (GO:0060998), positive regulation of dendritic spine morphogenesis (GO:0061003), positive regulation of synapse maturation (GO:0090129), regulation of protein localization to plasma membrane (GO:1903076), regulation of neuron migration (GO:2001222)

GO Molecular Function (13): actin binding (GO:0003779), calcium/calmodulin-dependent protein kinase activity (GO:0004683), calmodulin binding (GO:0005516), ATP binding (GO:0005524), identical protein binding (GO:0042802), protein homodimerization activity (GO:0042803), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (13): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), centrosome (GO:0005813), cytosol (GO:0005829), calcium- and calmodulin-dependent protein kinase complex (GO:0005954), postsynaptic density (GO:0014069), endocytic vesicle membrane (GO:0030666), sarcoplasmic reticulum membrane (GO:0033017), neuron projection (GO:0043005), cytoskeleton (GO:0005856), membrane (GO:0016020), sarcoplasmic reticulum (GO:0016529), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-14 pathways:

Category	Pathways
Activation of NMDA receptors and postsynaptic events	3
Oncogenic MAPK signaling	3
Post NMDA receptor activation events	2
Cardiac conduction	2
Calmodulin induced events	1
Cellular response to heat stress	1
Glutamate binding, activation of AMPA receptors and synaptic plasticity	1
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling	1
RAF/MAP kinase cascade	1
MAPK1/MAPK3 signaling	1
Interferon Signaling	1
Transcriptional Regulation by MECP2	1
Ion channel transport	1
Signaling by RAS mutants	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
regulation of synaptic plasticity	2
protein binding	2
protein kinase activity	2
bounding membrane of organelle	2
phosphorylation	1
protein modification process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
system development	1
regulation of neuron projection development	1
neuron projection development	1
positive regulation of cell projection organization	1
skeletal muscle adaptation	1
regulation of muscle adaptation	1
cellular developmental process	1
protein phosphorylation	1
regulation of neuronal synaptic plasticity	1
regulation of synapse organization	1
calcium ion transport	1
regulation of metal ion transport	1
positive regulation of synaptic transmission	1
regulation of developmental process	1
dendritic spine development	1
positive regulation of neuron projection development	1
positive regulation of dendrite morphogenesis	1
dendritic spine morphogenesis	1
positive regulation of dendritic spine development	1
regulation of dendritic spine morphogenesis	1
positive regulation of developmental process	1
positive regulation of cellular component organization	1
synapse maturation	1
regulation of synapse maturation	1
protein localization to plasma membrane	1
regulation of protein localization to cell periphery	1
regulation of protein localization to membrane	1
neuron migration	1

Protein interactions and networks

STRING

2298 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CAMK2B	CAMK2A	Q9UQM7	901
CAMK2B	CALM1	P02593	817
CAMK2B	CAMK2N2	Q96S95	816
CAMK2B	CALML5	Q9NZT1	806
CAMK2B	CALML3	P27482	805
CAMK2B	CALML4	Q96GE6	796
CAMK2B	CALML6	Q8TD86	792
CAMK2B	GRIN2B	Q13224	770
CAMK2B	ARC	Q7LC44	738
CAMK2B	DLG4	P78352	682
CAMK2B	GRIA3	P42263	645
CAMK2B	LRRC7	Q96NW7	637
CAMK2B	SYNGAP1	Q96PV0	582
CAMK2B	GRIA1	P42261	526
CAMK2B	SYT1	P21579	496

IntAct

178 interactions, top by confidence:

A	B	Type	Score
CAMK2B	CAMK2A	psi-mi:“MI:0915”(physical association)	0.850
MCM5	MCM3	psi-mi:“MI:0914”(association)	0.850
CAMK2B	CAMK2D	psi-mi:“MI:0407”(direct interaction)	0.820
CAMK2B	CAMK2D	psi-mi:“MI:0915”(physical association)	0.820
PKN3	ARHGAP10	psi-mi:“MI:0914”(association)	0.680
AP5B1	CAMK2B	psi-mi:“MI:0915”(physical association)	0.670
CAMK2B	AP5B1	psi-mi:“MI:0915”(physical association)	0.670
ZNF397	ZNF24	psi-mi:“MI:0914”(association)	0.640
PRKAG2	PRKAA2	psi-mi:“MI:0914”(association)	0.640
CALM	SOX9	psi-mi:“MI:0407”(direct interaction)	0.610
CAMK2B	CAMK2B	psi-mi:“MI:0915”(physical association)	0.590
CAMK2B	CAMK2B	psi-mi:“MI:0407”(direct interaction)	0.590
CAMK2B	CALM1	psi-mi:“MI:0407”(direct interaction)	0.590
CAMK2B		psi-mi:“MI:0915”(physical association)	0.560
CAMK2B	ACOT7	psi-mi:“MI:0915”(physical association)	0.560
CAMK2B	RBFOX2	psi-mi:“MI:0915”(physical association)	0.560
CAMK2B	KRTAP10-11	psi-mi:“MI:0915”(physical association)	0.560
CAMK2B	RAP2B	psi-mi:“MI:0915”(physical association)	0.560
CAMK2B	RPL11	psi-mi:“MI:0915”(physical association)	0.560
CAMK2B	KRTAP19-5	psi-mi:“MI:0915”(physical association)	0.560
KRTAP19-7	CAMK2B	psi-mi:“MI:0915”(physical association)	0.560
SPRYD7	CAMK2B	psi-mi:“MI:0915”(physical association)	0.560
FAM171A2	CAMK2B	psi-mi:“MI:0915”(physical association)	0.560
TTC5	CAMK2B	psi-mi:“MI:0915”(physical association)	0.560
RBPMS	CAMK2B	psi-mi:“MI:0915”(physical association)	0.560
PHKB	CAMK2B	psi-mi:“MI:0915”(physical association)	0.560
CAMK2B	POP5	psi-mi:“MI:0915”(physical association)	0.560
MED18	CAMK2B	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (203): CAMK2B (Two-hybrid), PHKB (Two-hybrid), RAP2B (Two-hybrid), RPL11 (Two-hybrid), MAD2L2 (Two-hybrid), MORF4L1 (Two-hybrid), RBPMS (Two-hybrid), ACOT7 (Two-hybrid), RBFOX2 (Two-hybrid), POP5 (Two-hybrid), MED18 (Two-hybrid), SPRYD7 (Two-hybrid), SEMA4G (Two-hybrid), MRPL11 (Two-hybrid), AP5B1 (Two-hybrid)

ESM2 similar proteins: A2RSY6, A2YNY4, A2YXJ7, A4QNR3, A5D7S3, A7P514, A8KBY2, A9UL13, A9UL14, B1ABR6, B1ABS0, B4R4H1, B5DUH6, B9GLX8, B9SVG9, D3ZYB7, F1R3W0, F7BLM1, O75460, O80443, O82677, P0CG38, P97358, Q08995, Q13554, Q29S07, Q2ABE5, Q32N22, Q3E7X8, Q3LXA7, Q3UAW9, Q496Z9, Q4JF75, Q4R318, Q4V8D6, Q66IW8, Q66WV0, Q6DDH2, Q84QM3, Q8C5W4

Diamond homologs: A0A509AFG4, A0A509AQE6, A0A5K1K8H0, A2ZVI7, A5A7I7, A5A7I8, B9FKW9, O15865, O49717, O80673, P08413, P15791, P28582, P28583, P28652, P49101, P53681, P53682, P53683, P53684, P62345, P93759, Q06850, Q0D715, Q0DYK7, Q10KY3, Q13554, Q13557, Q14012, Q1PE17, Q1PFH8, Q2HJF7, Q2QQR2, Q2QVG8, Q2QX45, Q2QY37, Q2RAV0, Q38868, Q38869, Q38870

SIGNOR signaling

27 interactions.

A	Effect	B	Mechanism
CAMK2B	up-regulates	PRKAA1	phosphorylation
CAMK2B	up-regulates	STAT1	phosphorylation
CAMK2B	down-regulates	GSK3A	phosphorylation
CAMK2B	down-regulates	CTNNB1	phosphorylation
CAMK2B	up-regulates	AMPK	phosphorylation
CAMK2B	“up-regulates activity”	CYLD	phosphorylation
CAMK2B	up-regulates	CYLD	phosphorylation
CAMK2B	“up-regulates activity”	SCN5A	phosphorylation
CAMK2B	“up-regulates activity”	SCN8A	phosphorylation
CAMK2B	“down-regulates quantity by destabilization”	GABBR1	phosphorylation
CAMK2B	down-regulates	STMN1	phosphorylation
CAMK2B	“up-regulates activity”	CAMK2B	phosphorylation
CAMK2B	“down-regulates activity”	ETS1	phosphorylation
CAMK2B	“up-regulates activity”	GRIN2B	phosphorylation
CAMK2B	unknown	PLCB3	phosphorylation
CAMK2B	“up-regulates activity”	RETREG1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 161 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
HSF1-dependent transactivation	6	18.5×	4e-04
Phase 0 - rapid depolarisation	5	16.8×	1e-03
Transcriptional Regulation by MECP2	5	15.4×	2e-03
Post NMDA receptor activation events	6	11.9×	1e-03
Activation of NMDA receptors and postsynaptic events	6	10.7×	2e-03
Signaling by BRAF and RAF1 fusions	5	8.3×	8e-03
Transmission across Chemical Synapses	7	5.2×	9e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	5	23.9×	5e-04
regulation of cytokinesis	5	14.9×	2e-03
G2/M transition of mitotic cell cycle	6	13.3×	9e-04
long-term synaptic potentiation	6	11.9×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

944 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	8
Likely pathogenic	8
Uncertain significance	342
Likely benign	477
Benign	42

Top pathogenic / likely-pathogenic (16)

Variant ID	HGVS	Classification
430920	NM_001220.5(CAMK2B):c.85C>T (p.Arg29Ter)	Pathogenic
430921	NM_001220.5(CAMK2B):c.328G>A (p.Glu110Lys)	Pathogenic
430923	NM_001220.5(CAMK2B):c.709G>A (p.Glu237Lys)	Pathogenic
430924	NM_001220.5(CAMK2B):c.820-1G>A	Pathogenic
430926	NM_001220.5(CAMK2B):c.903+1G>A	Pathogenic
4795448	NM_001220.5(CAMK2B):c.778C>G (p.Arg260Gly)	Pathogenic
560179	NM_001220.5(CAMK2B):c.638C>T (p.Pro213Leu)	Pathogenic
560180	NM_001220.5(CAMK2B):c.852A>T (p.Arg284Ser)	Pathogenic
1275799	NM_001220.5(CAMK2B):c.903+2T>C	Likely pathogenic
2023959	NM_001220.5(CAMK2B):c.441G>C (p.Lys147Asn)	Likely pathogenic
2499040	NM_001220.5(CAMK2B):c.1059+2T>C	Likely pathogenic
2506486	NM_001220.5(CAMK2B):c.601+1G>A	Likely pathogenic
3769908	NM_001220.5(CAMK2B):c.895A>G (p.Lys299Glu)	Likely pathogenic
4819025	NM_001220.5(CAMK2B):c.1834G>T (p.Glu612Ter)	Likely pathogenic
4849224	NM_001220.5(CAMK2B):c.596C>T (p.Ala199Val)	Likely pathogenic
981290	NM_001220.5(CAMK2B):c.885_902dup (p.Asn295_Leu300dup)	Likely pathogenic

SpliceAI

6114 predictions. Top by Δscore:

Variant	Effect	Δscore
7:44211021:A:AG	acceptor_gain	1.0000
7:44211022:G:GG	acceptor_gain	1.0000
7:44211022:GCAC:G	acceptor_gain	1.0000
7:44211125:G:GG	donor_gain	1.0000
7:44212245:A:G	acceptor_gain	1.0000
7:44220055:CTCA:C	donor_loss	1.0000
7:44220056:TCA:T	donor_loss	1.0000
7:44220057:CAC:C	donor_loss	1.0000
7:44220058:A:AC	donor_gain	1.0000
7:44220058:A:AT	donor_loss	1.0000
7:44220058:ACCTT:A	donor_gain	1.0000
7:44220059:C:CC	donor_gain	1.0000
7:44220059:C:G	donor_loss	1.0000
7:44220059:CCTT:C	donor_gain	1.0000
7:44220059:CCTTC:C	donor_gain	1.0000
7:44220290:CAGCA:C	acceptor_gain	1.0000
7:44220291:AGCA:A	acceptor_gain	1.0000
7:44220292:GCA:G	acceptor_gain	1.0000
7:44220293:CA:C	acceptor_gain	1.0000
7:44220293:CAC:C	acceptor_gain	1.0000
7:44220294:ACTGT:A	acceptor_loss	1.0000
7:44220295:C:CC	acceptor_gain	1.0000
7:44220303:A:T	acceptor_gain	1.0000
7:44220305:C:CT	acceptor_gain	1.0000
7:44220306:A:T	acceptor_gain	1.0000
7:44220605:T:TA	donor_gain	1.0000
7:44220610:A:AC	donor_gain	1.0000
7:44220611:C:CC	donor_gain	1.0000
7:44220611:CTCA:C	donor_gain	1.0000
7:44220614:A:AC	donor_gain	1.0000

AlphaMissense

4331 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:44220113:C:A	W650C	1.000
7:44220113:C:G	W650C	1.000
7:44220115:A:G	W650R	1.000
7:44220115:A:T	W650R	1.000
7:44220134:C:A	W643C	1.000
7:44220134:C:G	W643C	1.000
7:44220136:A:G	W643R	1.000
7:44220136:A:T	W643R	1.000
7:44220141:C:G	R641P	1.000
7:44220198:A:G	L622P	1.000
7:44220201:C:G	R621P	1.000
7:44220210:G:T	A618D	1.000
7:44220215:G:C	C616W	1.000
7:44220217:A:G	C616R	1.000
7:44220255:A:G	L603P	1.000
7:44220258:A:T	I602N	1.000
7:44220657:A:G	L576P	1.000
7:44220857:C:G	A548P	1.000
7:44220865:A:G	L545P	1.000
7:44240727:A:G	L309P	1.000
7:44240739:A:G	L305P	1.000
7:44240749:C:G	G302R	1.000
7:44240749:C:T	G302R	1.000
7:44241704:A:G	L300P	1.000
7:44241709:T:A	R298S	1.000
7:44241709:T:G	R298S	1.000
7:44241710:C:A	R298I	1.000
7:44241710:C:G	R298T	1.000
7:44241721:G:C	F294L	1.000
7:44241721:G:T	F294L	1.000

dbSNP variants (sampled 300 via entrez): RS1000005743 (7:44325623 C>T), RS1000050549 (7:44246435 CCACA>C,CCA), RS1000097920 (7:44219208 C>T), RS1000100361 (7:44272760 C>G), RS1000129323 (7:44283501 G>A), RS1000129901 (7:44272491 G>A), RS1000161524 (7:44287092 C>T), RS1000161942 (7:44283232 T>A,C), RS1000208433 (7:44290885 G>A,C), RS1000229640 (7:44240887 A>C,G), RS1000244638 (7:44256259 G>A), RS1000281510 (7:44316070 T>C), RS1000328461 (7:44267875 G>A), RS1000341681 (7:44245504 T>C), RS1000350905 (7:44288552 A>G)

Disease associations

OMIM: gene MIM:607707 | disease phenotypes: MIM:617799, MIM:619681, MIM:616579

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability, autosomal dominant 40	Definitive	Autosomal dominant
intellectual disability, autosomal dominant 54	Strong	Autosomal dominant
autosomal dominant non-syndromic intellectual disability	Supportive	Autosomal dominant

Mondo (11): intellectual disability, autosomal dominant 54 (MONDO:0030920), intellectual disability (MONDO:0001071), hereditary ataxia (MONDO:0100309), neurodevelopmental disorder (MONDO:0700092), dystonia, early-onset, and/or spastic paraplegia (MONDO:0859215), intellectual disability, autosomal dominant 40 (MONDO:0014699), autism spectrum disorder (MONDO:0005258), microcephaly (MONDO:0001149), congenital nervous system disorder (MONDO:0002320), dystonic disorder (MONDO:0003441), autosomal dominant non-syndromic intellectual disability (MONDO:0015802)

Orphanet (4): Hereditary ataxia (Orphanet:183518), CHAMP1-related intellectual disability-facial dysmorphism-behavioral abnormalities syndrome (Orphanet:692193), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

64 total (30 of 64 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000016	Urinary retention
HP:0000252	Microcephaly
HP:0000331	Short chin
HP:0000340	Sloping forehead
HP:0000341	Narrow forehead
HP:0000483	Astigmatism
HP:0000486	Strabismus
HP:0000490	Deeply set eye
HP:0000505	Visual impairment
HP:0000565	Esotropia
HP:0000639	Nystagmus
HP:0000678	Dental crowding
HP:0000680	Delayed eruption of primary teeth
HP:0000687	Widely spaced teeth
HP:0000718	Aggressive behavior
HP:0000729	Autistic behavior
HP:0000737	Irritability
HP:0000750	Delayed speech and language development
HP:0000817	Reduced eye contact
HP:0000958	Dry skin
HP:0000964	Eczematoid dermatitis
HP:0000970	Anhidrosis
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001251	Ataxia
HP:0001252	Hypotonia
HP:0001263	Global developmental delay
HP:0001272	Cerebellar atrophy
HP:0001344	Absent speech

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001436_15	Metabolic syndrome	9.000000e-11
GCST002155_1	Osteoarthritis (hip)	8.000000e-10
GCST005576_13	Intracranial aneurysm	1.000000e-06
GCST006998_3	Cerebrospinal fluid p-tau levels in mild cognitive impairment	4.000000e-07
GCST007267_321	Systolic blood pressure	4.000000e-08
GCST010244_338	Triglyceride levels	8.000000e-14

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0000195	metabolic syndrome
EFO:0004760	t-tau measurement
EFO:0006335	systolic blood pressure
EFO:0004530	triglyceride measurement

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D020821	Dystonic Disorders	C10.228.662.300
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D065886	Neurodevelopmental Disorders	F03.625
C531684	Hereditary spinal ataxia (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2097164 (PROTEIN FAMILY), CHEMBL4121 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

25 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 330,238 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1336	SORAFENIB	4	86,060
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL189963	PALBOCICLIB	4	13,102
CHEMBL3301610	ABEMACICLIB	4	7,045
CHEMBL535	SUNITINIB	4	79,020
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL300138	ENZASTAURIN	3	3,209
CHEMBL223360	LINIFANIB	3	3,925
CHEMBL428690	ALVOCIDIB	3	27,781
CHEMBL491473	CEDIRANIB	3	9,098
CHEMBL50	QUERCETIN	3	74,559
CHEMBL603469	LESTAURTINIB	3
CHEMBL103667	DORAMAPIMOD	2	1,681
CHEMBL1721885	SU-014813	2	363
CHEMBL1967878	CENISERTIB	2	358
CHEMBL1980297	ILORASERTIB	2	581
CHEMBL362558	LY-2090314	2	108
CHEMBL384304	RG-547	2	93
CHEMBL513909	BI-2536	2	895
CHEMBL565612	SOTRASTAURIN	2
CHEMBL1908394	GSK-461364	1
CHEMBL4439321	ATUVECICLIB	1
CHEMBL482767	SNS-314	1
CHEMBL482967	CYC-116	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CAMK2 family

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
staurosporine	Inhibition	10.0	pIC50

Binding affinities (BindingDB)

4 measured of 6 human assays (6 total across all organisms); most potent 4 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
PKC-412	KD	190 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM

ChEMBL bioactivities

294 potent at pChembl≥5 of 306 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.22	IC50	0.0599	nM	STAUROSPORINE
10.19	IC50	0.0642	nM	STAUROSPORINE
10.15	IC50	0.07	nM	STAUROSPORINE
10.02	IC50	0.0945	nM	STAUROSPORINE
9.05	Kd	0.882	nM	CHEMBL5653589
8.89	Kd	1.3	nM	STAUROSPORINE
8.70	IC50	2	nM	STAUROSPORINE
8.52	Kd	3	nM	STAUROSPORINE
8.46	IC50	3.5	nM	ABEMACICLIB
8.40	IC50	4	nM	STAUROSPORINE
8.23	ED50	5.896	nM	CHEMBL5653589
8.22	IC50	6	nM	STAUROSPORINE
7.92	Kd	12	nM	CHEMBL4576489
7.72	Kd	19	nM	CHEMBL4465866
7.60	IC50	25	nM	CHEMBL312292
7.60	IC50	25	nM	STAUROSPORINE AGLYCON
7.50	IC50	32	nM	CHEMBL2369378
7.44	IC50	36	nM	CHEMBL385035
7.34	IC50	46	nM	CHEMBL75368
7.31	IC50	49	nM	CHEMBL73764
7.24	IC50	58	nM	CHEMBL59785
7.23	Kd	59	nM	LESTAURTINIB
7.21	IC50	62	nM	CHEMBL307630
7.16	IC50	70	nM	CHEMBL1231206
7.10	Ki	79.43	nM	CHEMBL1966628
7.09	IC50	82	nM	CHEMBL292021
7.09	IC50	81	nM	CHEMBL72808
7.08	IC50	83	nM	CHEMBL1945559
7.05	IC50	90	nM	CHEMBL308979
7.04	IC50	92	nM	CHEMBL293157
7.02	IC50	95	nM	CHEMBL76326
7.00	Ki	100	nM	CHEMBL1986943
7.00	Ki	100	nM	CHEMBL1974870
7.00	Ki	100	nM	CHEMBL1998159
7.00	Ki	100	nM	CHEMBL1970903
6.76	IC50	174	nM	CHEMBL293898
6.76	IC50	174	nM	CHEMBL72076
6.75	IC50	177	nM	CHEMBL306047
6.74	IC50	184	nM	STAUROSPORINONE
6.70	Ki	199.5	nM	CHEMBL1988537
6.68	Kd	210	nM	MIDOSTAURIN
6.67	IC50	216	nM	CHEMBL307152
6.63	IC50	236	nM	CHEMBL64742
6.60	Ki	251.2	nM	CHEMBL1973540
6.60	Ki	251.2	nM	CHEMBL2001751
6.60	Ki	251.2	nM	CHEMBL1991063
6.58	IC50	266	nM	CHEMBL76337
6.52	IC50	301	nM	CHEMBL430606
6.51	Kd	310	nM	RUXOLITINIB
6.50	Ki	316.2	nM	CHEMBL1995813

PubChem BioAssay actives

88 with measured affinity, of 1652 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1350959: Inhibition of CAMK2b (unknown origin)	ic50	0.0001	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147983: Binding affinity to human CAMK2B incubated for 45 mins by Kinobead based pull down assay	kd	0.0009	uM
Abemaciclib	2199001: Inhibition of human CAMK2beta preincubated with compound for 20 mins followed by [33P]ATP addition and measured after 2 hrs by filter binding method	ic50	0.0035	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-methylamino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526288: Binding affinity to recombinant human full length N-terminal GST-tagged CAMK2B expressed in baculovirus expression system using GS peptide as substrate incubated for 1 hr in presence of calmodulin by TR-FRET assay	kd	0.0120	uM
3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)-N-[2-[2-[2-[2-[[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]propanamide	1526288: Binding affinity to recombinant human full length N-terminal GST-tagged CAMK2B expressed in baculovirus expression system using GS peptide as substrate incubated for 1 hr in presence of calmodulin by TR-FRET assay	kd	0.0190	uM
3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaene-12,14-dione	45962: Inhibition of Calcium/calmodulin-dependent protein kinase type II	ic50	0.0250	uM
1-[2-(18-methyl-12,14-dioxo-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaen-5-yl)ethyl]piperidine-4-carboxamide	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.0250	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-6-[(2-nitrophenyl)methoxycarbonylamino]hexanoyl]amino]-6-[(2-nitrophenyl)methoxycarbonylamino]hexanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-4-methylpentanoic acid	220482: Inhibitory activity of compound against CaMKII	ic50	0.0320	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[(2-nitrophenyl)methoxycarbonylamino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-4-methylpentanoic acid	220482: Inhibitory activity of compound against CaMKII	ic50	0.0360	uM
5-[2-(4-hydroxypiperidin-1-yl)ethyl]-18-methyl-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.0460	uM
5-[2-[(4-hydroxycyclohexyl)amino]ethyl]-18-methyl-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.0490	uM
8-bromo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17,19,21-nonaene-12,14-dione	45967: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II using autocamtide as substrate	ic50	0.0580	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507856: Binding affinity to CAMK2B	kd	0.0590	uM
18-methyl-5-(2-piperidin-1-ylethyl)-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.0620	uM
methyl 1-[2-(18-methyl-12,14-dioxo-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaen-5-yl)ethyl]piperidine-4-carboxylate	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.0810	uM
6-methyl-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17,19,21-nonaene-12,14-dione	45967: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II using autocamtide as substrate	ic50	0.0820	uM
7,8-dichloro-9-methyl-1-oxospiro[2,4-dihydropyrido[3,4-b]indole-3,4’-piperidine]-4-carbonitrile	643791: Inhibition of CaMK2 using ATP as substrate	ic50	0.0830	uM
5-[2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl]-18-methyl-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.0900	uM
6-fluoro-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17,19,21-nonaene-12,14-dione	45967: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II using autocamtide as substrate	ic50	0.0920	uM
5-[2-(2-hydroxyethylamino)ethyl]-18-methyl-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.0950	uM
20-bromo-3-methyl-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17(22),18,20-nonaene-12,14-dione	45967: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II using autocamtide as substrate	ic50	0.1740	uM
5-[3-(diethylamino)propyl]-18-methyl-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.1740	uM
18-methyl-5-(2-morpholin-4-ylethyl)-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.1770	uM
3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-12-one	45962: Inhibition of Calcium/calmodulin-dependent protein kinase type II	ic50	0.1840	uM
Midostaurin	435394: Binding constant for CAMK2B kinase domain	kd	0.2100	uM
5-[3-[(4-hydroxycyclohexyl)amino]propyl]-18-methyl-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.2160	uM
6-methoxy-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17,19,21-nonaene-12,14-dione	45967: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II using autocamtide as substrate	ic50	0.2360	uM
5-[3-(2-hydroxyethylamino)propyl]-18-methyl-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.2660	uM
18-methyl-5-(2-piperazin-1-ylethyl)-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.3010	uM
Ruxolitinib	624827: Binding constant for CAMK2B kinase domain	kd	0.3100	uM
18-methyl-5-[3-(4-methylpiperazin-1-yl)propyl]-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.3820	uM
18-methyl-5-(2-thiomorpholin-4-ylethyl)-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.4030	uM
18-methyl-5-(3-morpholin-4-ylpropyl)-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.5160	uM
3-[2-(2-hydroxyethylamino)ethyl]-6-methoxy-18-methyl-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4(9),5,7,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.5270	uM
3-[3-(2-hydroxyethylamino)propyl]-6-methoxy-18-methyl-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4(9),5,7,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	0.7320	uM
20-ethyl-17,23-dioxa-4,14,20,26-tetrazahexacyclo[24.6.1.17,14.02,6.08,13.027,32]tetratriaconta-1(33),2(6),7(34),8,10,12,27,29,31-nonaene-3,5-dione	45969: Inhibition of Calcium/calmodulin-dependent protein kinase type II	ic50	0.7800	uM
[4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone	624827: Binding constant for CAMK2B kinase domain	kd	0.8900	uM
6-chloro-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17,19,21-nonaene-12,14-dione	45967: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II using autocamtide as substrate	ic50	0.9140	uM
(2S)-1-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-3-phenylpropan-2-amine	624827: Binding constant for CAMK2B kinase domain	kd	0.9700	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-4-methyl-2-[[(2S)-2-(phenylmethoxycarbonylamino)propanoyl]amino]pentanoyl]amino]pentanoyl]amino]pentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-4-methylpentanoic acid	220482: Inhibitory activity of compound against CaMKII	ic50	1.0000	uM
3-[2-[(4-hydroxycyclohexyl)amino]ethyl]-6-methoxy-18-methyl-3,13,18-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4(9),5,7,11(15),17(21),19,22-nonaene-12,14-dione	45968: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II	ic50	1.1700	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[(2-nitrophenyl)methoxycarbonylamino]hexanoyl]amino]-6-[(2-nitrophenyl)methoxycarbonylamino]hexanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-4-methylpentanoic acid	220482: Inhibitory activity of compound against CaMKII	ic50	1.2000	uM
7-bromo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17,19,21-nonaene-12,14-dione	45967: Inhibitory activity against Calcium/calmodulin-dependent protein kinase type II using autocamtide as substrate	ic50	1.2500	uM
Sunitinib	435394: Binding constant for CAMK2B kinase domain	kd	1.4000	uM
Palbociclib	2199001: Inhibition of human CAMK2beta preincubated with compound for 20 mins followed by [33P]ATP addition and measured after 2 hrs by filter binding method	ic50	1.6000	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	624827: Binding constant for CAMK2B kinase domain	kd	1.9000	uM
3-(1-methylindol-3-yl)-4-(1-piperidin-4-ylindol-3-yl)pyrrole-2,5-dione	45084: Inhibition of purified mammalian brain [Ca(2+)]/Calmodulin dependent kinase	ic50	2.0000	uM
3-(1-methylindol-3-yl)-4-[1-(1-methylpiperidin-4-yl)indol-3-yl]pyrrole-2,5-dione	45084: Inhibition of purified mammalian brain [Ca(2+)]/Calmodulin dependent kinase	ic50	2.0000	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	435394: Binding constant for CAMK2B kinase domain	kd	2.3000	uM
3-(4-imidazo[1,2-a]pyridin-3-yl-2,5-dioxopyrrol-3-yl)-N,N-dimethyl-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraene-10-carboxamide	241780: Inhibition of human Calcium/calmodulin-dependent protein kinase type II	ic50	2.5000	uM

CTD chemical–gene interactions

65 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Particulate Matter	affects cotreatment, increases expression, decreases expression, increases abundance	4
Benzo(a)pyrene	affects methylation, increases methylation, increases mutagenesis	3
Aflatoxin B1	decreases expression, decreases methylation	2
aminomethylphosphonic acid (AMPA)	decreases expression	1
lead acetate	decreases expression	1
quercitrin	decreases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
cypermethrin	increases expression	1
sodium arsenite	affects expression	1
benzo(e)pyrene	increases methylation	1
ferrous chloride	decreases expression	1
aflatoxin B2	affects methylation	1
cupric chloride	decreases expression	1
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid	affects cotreatment, increases expression	1
cyfluthrin	increases expression	1
azoxystrobin	decreases expression	1
deguelin	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
Chir 99021	affects cotreatment, increases expression	1
pyrimidifen	decreases expression	1
nutlin 3	affects cotreatment, increases expression	1
thifluzamide	decreases expression	1
pyrachlostrobin	decreases expression	1
bisphenol S	decreases methylation	1
LDN 193189	affects cotreatment, increases expression	1
picoxystrobin	decreases expression	1
3-(4-pyridyl)-1H-indole	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Glyphosate	increases expression	1
Air Pollutants	decreases expression, increases abundance	1

ChEMBL screening assays

314 unique, capped per target: 313 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2422678	Binding	Inhibition of CaMK2alpha/CaMK2beta/CaMK2delta/CaMK2gamma in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	Hit-to-lead optimization and kinase selectivity of imidazo[1,2-a]quinoxalin-4-amine derived JNK1 inhibitors. — Bioorg Med Chem Lett
CHEMBL1963787	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CAMK2B	PubChem BioAssay data set

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9AU	Ubigene HEK293 CAMK2B KO	Transformed cell line	Female

Clinical trials (associated diseases)

299 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00202397	PHASE2	COMPLETED	Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood